152148-65-7Relevant academic research and scientific papers
ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT
-
Page/Page column 274; 275; 291; 292, (2021/12/31)
Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS
-
Page/Page column 127-128, (2011/04/26)
The present application provides substituted purine derivatives and related compounds of the formulas shown. These com ounds are useful as inhibitors of HSP90, and hence in the treatment of related diseases. (Formulae) Z1-Z3, Xa-Xc, X2, X4, Y and R are as defined in the specification.
Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
-
, (2008/06/13)
The present invention relates to compounds of formula (I): 1in which R1 represents a hydrogen or halogen atom, or a group CF3; R2 and R3 represent, independently, a hydrogen atom or a methyl group; n and n′ each
Structure-activity studies for a novel series of N-(arylethyl)-N- (1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines possessing dual 5- HT uptake inhibiting and α2-antagonistic activities
Meyer, Michael D.,Hancock, Arthur A.,Tietje, Karin,Sippy, Kevin B.,Prasad, Rajnandan,Stout, David M.,Arendsen, David L.,Donner, B. Greg,Carroll, William A.
, p. 1049 - 1062 (2007/10/03)
In search of an α2-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the α2-receptor (K(i) = 6.71 nM) and
